Healthcare Industry News:  nanoparticles 

Devices Oncology

 News Release - November 3, 2009

Nanostart Majority-Owned MagForce Announces Successful Completion of Final Clinical Trials For Nano-Cancer(R) Therapy

Study objective significantly exceeded

Median survival time doubled

Therapy shown to be highly effective, with minimal side effects

Application for EU regulatory approval to be submitted before end of year

FRANKFURT & BERLIN--(HSMN NewsFeed)--MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Nano-Cancer(R) therapy in patients with recurrent glioblastoma, a frequent form of brain tumor which is highly malignant. The actual study results significantly exceeded the study objective.

According to a previous study among a large patient population, the median survival time following diagnosis of a glioblastoma recurrence and treatment with conventional therapy (surgery, chemotherapy and radiation) is 6.2 months. The primary objective for the Nano-Cancer(R) therapy study was to demonstrate an extension of the median survival time in the recruited patient group by three months compared to this historical control group.

In fact, the median survival time of the 59 patients participating in these trials was 13.4 months following treatment with Nano-Cancer(R) therapy in conjunction with radiation. The median survival time was thus significantly greater, more than double that of the control population.

The results were even more remarkable in that Nano-Cancer(R) therapy was tested not on newly diagnosed patients with primary tumors but rather as a study involving patients who had already endured treatment with conventional therapies, as well as the unpleasant effects generally associated with these. Following regulatory approval of the new therapy, it is expected that it will also be available for use in treating other types of localized tumors, as these are generally responsive to the same principle of using warmth to destroy or degrade cancer cells.

MagForce founder and chief scientific officer Dr. Andreas Jordan commented, “The results demonstrate the potential of Nano-Cancer(R) therapy, which at the same time has minimal patient side effects. Our vision is to establish this new technology alongside surgery, chemotherapy and radiation as an additional pillar of cancer therapy.”

Marco Beckmann, CEO of Nanostart AG, went on to add, “We enthusiastically congratulate Dr. Jordan and his team on the superb study results. It is my belief that we may thank nanotechnology for a historical advance in medical science.”

In addition to its high efficacy of which has now been conclusively demonstrated, Nano-Cancer(R) therapy offers an additional and very significant advantage compared to the existing conventional therapy alternatives of surgical intervention, chemotherapy and radiation: Nano-Cancer(R) therapy is tolerated extremely well by patients and, despite its high efficacy, has no serious or unpleasant side effects.

The results of these clinical trials will now form the basis of application for EU regulatory approval for the new therapy, which will be submitted before the end of this year. Once EU regulatory approval has been obtained, MagForce will be able to market its Nano-Cancer(R) therapy throughout the European Union. The detailed study results will be published shortly in a medical journal.

Nano-Cancer(R) therapy represents a completely new way to fight cancer and is the world’s first approach to use magnetic nanoparticles to treat tumors with virtually no side effects. This is done by injecting specially coated iron oxide nanoparticles directly and precisely into the tumor so that they remain concentrated in the tumor and do not diffuse into the surrounding healthy tissue. The nanoparticles within the tumor are then heated to an exact temperature by externally applying an external magnetic field. In this way, tumor temperatures of up to 70°C (158°F) can be precisely attained within a fraction of a degree. This heat damages the tumor or destroys it completely. During the treatment procedure, patients feel only a moderate warming sensation.

Nanostart AG has been Lead Investor in MagForce Nanotechnologies since 2004 and currently holds approx. 77% of its shares.

About Nanostart

Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit

About MagForce Nanotechnologies:

MagForce Nanotechnologies AG is the world’s leading company in the area of nanotechnology-based cancer treatment. Its patented therapy allows the targeted destruction of tumors using magnetic nanoparticles. MagForce’s nanotechnology represents a revolutionary approach to the future successful treatment of solid tumors. For more information, please visit

Disclaimer: This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.

Source: Nanostart

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.